Patents
Method for in vitro culture of mammalian cells
Patent Number: 5223428This patent teaches methods of culturing and expanding cells, including stem cells, through a unique culture system that uses hollow fiber technology. Since tissue culture is usually performed under static conditions and very derived from the in vivo situation, numerous failures to expand stem cells can be explained. The culture system of this invention seeks to provide a more in vivo like...
Inventor: Rose, Sam (San Francisco, CA)
Assignee: Baxter International Inc. (Deerfield, IL)
Date of First Priority Issue: Tuesday December 14th, 1982
SCL: a hematopoietic growth and differentiation factor
Patent Number: 5214133This patent is for a transcription factor associated with stem cell activity. The factor is a basic helix-loop-helix transcription factor called SCL/Tal1. It is expressed in cells that possess hematopoietic stem cell activity and controls numerous genes associated with stem cell functions. Modification of activity of this transcription factor may be used theoretically for manipulation...
Inventors: Kirsch, Ilan R. (Potomac, MD); Begley, C. Glenn (North Carlton, AU)
Assignee: The United States of America as represented by the Secretary of the (Washington, DC)
Date of First Priority Issue: Friday November 17th, 1989
IL-4 and TNF induce mAb 6G10-recognized expression on bone marrow stromal cells
Patent Number: 5206345This patent covers a molecule associated with adhesion of cells to the endothelium that is induced by IL-4 and TNF and is recognized by the antibody 6G10 . This molecule may be important in order to alter migration not only of stem cells but also in situations where migration of cells is sought to be avoided such as cancer.
Inventors: Masinovsky, Boris (Bellevue, WA); Gallatin, William M. (Mercer Island, WA); Simmons, Paul J. (Seattle, WA)
Assignee: Fred Hutchinson Cancer Research Center (Seattle, WA)
Date of First Priority Issue: Thursday August 2nd, 1990
Pharmaceutical composition of BUF-5 for treating anemia
Patent Number: 5200395This patent covers the use of a peptide called BUF-5 for the treatment of anemia. Based on the literature we could not find what exactly BUF-5 is. This could be a very interesting patent for treatment not only of various forms of anemia, but also other hematological diseases in which stimulation of the erythrocyte progenitor is beneficial.
Inventors: Eto, Yuzuru (Kawasaki, JP); Koyama, Naoto (Kawasaki, JP); Ejima, Daisuke (Kawasaki, JP); Washitake, Masayo (Kawasaki, JP); Shibai, Hiroshiro (Kawasaki, JP)
Assignee: Ajinomoto Company, Inc. (Tokyo, JP)
Date of First Priority Issue: Sunday October 18th, 1998
Method for improving autologous transplantation
Patent Number: 5199942Anyone performing autologous hematopoietic stem cell transplants should watch out for this patent !! This patent teaches essentially autologous transplantation with ex vivo expansion of stem cells. Numerous companies and scientists are doing or have done clinical investigations which potentially infringe on this patent.
Inventor: Gillis, Steven (Mercer Island, WA)
Assignee: Immunex Corporation (Seattle, WA)
Date of First Priority Issue: Friday June 7th, 1991
Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells
Patent Number: 5197985Mesenchymal stem cells are a topic of intense investigation and subject to several clinical trials, including by Osiris Therapeutics who are currently in Phase III for treatment of graft versus host disease. This is one of the older patents on mesenchymal stem cells that teaches the differentiation of mesenchymal stem cells into bone forming cells. This is performed through the use of...
Inventors: Caplan, Arnold I. (Cleveland Heights, OH); Haynesworth, Stephen E. (Cleveland Heights, OH)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday November 16th, 1990
Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use
Patent Number: 5192553This is a patent on freezing cord blood stem cells. This is an important patent since it is generating revenue. The company Pharmastem used this patent and several others in order to position itself in the cord blood industry. Additionally, this patent stood the test of litigation.
Inventors: Boyse, Edward A. (Tucson, AZ); Broxmeyer, Hal E. (Indianapolis, IN); Douglas, Gordon W. (New York, NY)
Assignee: Biocyte Corporation (New York, NY)
Date of First Priority Issue: Thursday November 12th, 1987
Method for stimulating transplanted bone marrow cells
Patent Number: 5187193This patent teaches the in vivo use of dithiocarbamate for hematopoietic reconstitution after bone marrow transplantation or myelosuppression. The dithiocarbamate or its analogs that are mentioned in the patent may be administered systemically without adverse effects.
Inventors: Borch, Richard F. (Pittsford, NY); Schmalbach, Therese K. (Newton, MA)
Assignee: University of Rochester (Rochester, NY)
Date of First Priority Issue: Monday September 12th, 1988
Composition and method for supporting bone marrow transplantation
Patent Number: 5186931This patent provides a composition of cytokines for stimulating hematopoiesis after a bone marrow transplant, as well as for the in vitro stimulation of hematopoiesis. The composition involves B cell differentiation factor and some commonly used cytokines today.
Inventors: Kishimoto, Tadamitsu (Nakano Tondabayashi-shi, Oosaka-fu, JP); Hirano, Toshio (Ibaraki, JP); Akiyama, Yukio (Kawasaki, JP); Okano, Akira (Kawasaki, JP); Matsui, Hiroshi (Kawasaki, JP); Takahara, Yoshiyuki (Kawasaki, JP)
Assignee: Ajinomoto Co., Inc. (Tokyo, JP); Kishimoto, Tadamitsu (Tondabayashi, JP)
Date of First Priority Issue: Wednesday August 6th, 1986
Preparation of pure cultures of post-mitotic human neurons
Patent Number: 5175103This patent covers one of the few stem cell therapies that actually entered clinical trials. The patent is for a teratocarcinoma cell line that is induced to differentiate into neurons with retinoic acid (and/or other factors) and then stops proliferating and can be used for cell therapy in stroke. The technology was eventually developed clinically by Layton Biosciences. Administration of the...
Inventors: Lee, Virginia (Philadelphia, PA); Pleasure, Samuel (Philadelphia, PA)
Assignee: Trustees of University of Pennsylvania (Philadelphia, PA)
Date of First Priority Issue: Monday October 21st, 1991